PSMA PET/CT Scans for Detecting Prostate and Liver Cancer Spread
Tests a PSMA imaging scan to find cancer in adults with prostate or liver cancer.
Plain-language title generated from the registry record
Registry title: Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
Key facts
- Where
- Hefei, Qingdao, and Tianjin, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with suspected, newly diagnosed or previously treated cancer who have a PSMA PET/CT scan planned. It studies how useful this scan is for finding the main tumour and its spread.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Suspected, newly diagnosed or previously treated malignant (cancerous) tumours, such as prostate cancer or liver cancer.
Main reasons for not taking part
- Non-malignant (non-cancerous) lesions
- Pregnancy
- Unable or unwilling to give written informed consent
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06690970, who can take part
Where in China
- The First Affiliated Hospital of University of Science and Technology of ChinaHefei, ChinaContact: Qiang Xie, PhDTaking people
- The Affiliated Hospital of Qingdao UniversityQingdao, ChinaContact: Guangjie Yang, MDTaking people
- Tianjin Medical University General HospitalTianjin, ChinaContact: Haonan Yu, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tianjin Medical University
- Trial code
- NCT06690970
- Record updated
- 8 September 2026
- Original description
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients (prostate cancer, hepatic cancer, etc.).Read full original descriptionShow less
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients (prostate cancer, hepatic cancer, etc.).
Inclusion: (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion: (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.